TWST logo

Twist Bioscience Corporation (TWST)

$112

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TWST

Market cap

$7.64B

EPS

-2.08

P/E ratio

--

Price to sales

24.53

Dividend yield

--

Beta

2.250385

Price on TWST

Previous close

$105.04

Today's open

$106.74

Day's range

$102.82 - $112.24

52 week range

$24.41 - $219.71

Profile about TWST

CEO

Emily M. Leproust

Employees

278

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

68178692

Issue type

Common Stock

TWST industries and sectors

Healthcare

Medical Diagnostics & Screening

News on TWST

Artisan Global Discovery Fund Q3 2026 Portfolio Activity

During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.

news source

Seeking Alpha • 5 hours ago

news preview

Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech

I believe TWST can, over time, capture more of a customer's R&D budget if initial DNA orders lead to more repeat testing and lab data work. TWST's AI drug discovery is at the heart of my growth bull case. But their diagnostics services also dovetail nicely because they could create additional demand. As customers scale personalized cancer testing, TWST could see more demand for its custom panels.

news source

Seeking Alpha • Nov 16, 2026

news preview

Twist Bioscience: 3 Key Takeaways for Long-Term Investors

Fourth-quarter revenue grew 28% year over year to $126.6 million. AI drug discovery revenue reached $59.1 million in fiscal 2026.

news source

The Motley Fool • Nov 12, 2026

news preview

This Biotech's Guidance Seemingly Beat Expectations — But A Twist Slammed The Stock

Twist Bioscience stock took a header Thursday on artificial intelligence nuances tied to its fiscal year 2027 guidance.

news source

Investors Business Daily • Nov 12, 2026

news preview

Twist Bioscience Q4 Earnings Call Highlights

Twist Bioscience NASDAQ: TWST reported 28% revenue growth and positive adjusted EBITDA for its fiscal fourth quarter, as demand for DNA, proteins and data used in AI drug discovery helped drive a 22% increase in full-year sales.

news source

MarketBeat • Nov 12, 2026

news preview

Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2026 earnings report and the investor presenta.

news source

Business Wire • Nov 12, 2026

news preview

Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.45 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Alger Mid Cap 40 ETF Q3 2026 Portfolio Review

Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from rising internet traffic, growing cybersecurity needs, and enterprise adoption of AI. FTAI shares detracted from performance during the quarter despite continued growth in its engine products business and progress on adapting mature aircraft engines for data center power generation.

news source

Seeking Alpha • Nov 12, 2026

news preview

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (“RSUs”) will be granted to 19 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and.

news source

Business Wire • Nov 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Twist Bioscience Corporation

Open an M1 investment account to buy and sell Twist Bioscience Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TWST on M1